Skip to content

Comparison of the effects of Dracocephalum and Rosa Damascene capsule on sleep disorder in heart failure patients

Comparison of the effects of Dracocephalum and Rosa Damascene capsule on sleep disorder in heart failure patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240316061309N1
Enrollment
80
Registered
2024-05-17
Start date
2024-04-08
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Sleep disorder. Condition 2: Heart failure. Other sleep disorders not due to a substance or known physiological condition Heart failure

Interventions

Intervention 1: First intervention group: Recipients of two Dracocephalum plant capsules made by the Health Technology Development Center, Nahal Gostar Chaharmahal Company office, registration number

Sponsors

Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Definitive diagnosis of heart failure with echo based on EF less than or equal to 40% confirmation of cardiologist Having a sleep disorder with a score of 5 or more from the Petersburg sleep disorder instrument despite taking sedatives Desire and informed consent of the patient

Exclusion criteria

Exclusion criteria: The client's unwillingness to continue cooperation at any time of the study use of complementary therapies or other drugs affecting sleep concurrently without coordination during the study The occurrence of acute problems leads to changes in the treatment process and the death of the patient

Design outcomes

Primary

MeasureTime frame
Sleep disorder. Timepoint: In the pre-intervention period, one day after the first dose, the eighth day after the administration. Method of measurement: Petersburg Sleep Disorder Questionnaire.

Secondary

MeasureTime frame
Anxiety. Timepoint: In the pre-intervention period, one day after the first dose, the eighth day after the administration. Method of measurement: Spielberger anxiety questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohsen Taghadosi

Kashan University of Medical Sciences

Taghadosi_m@kaums.ac.ir+98 31 5558 9392

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026